Literature DB >> 23060930

Prognostic factors for colectomy in refractory ulcerative colitis treated with calcineurin inhibitors.

Shigeki Bamba1, Akira Andoh, Hirotsugu Imaeda, Hiromitsu Ban, Ayako Kobori, Yousuke Mochizuki, Makoto Shioya, Takashi Nishimura, Osamu Inatomi, Masaya Sasaki, Yasuharu Saitoh, Tomoyuki Tsujikawa, Yoshihide Fujiyama.   

Abstract

Calcineurin inhibitors (CNIs) such as cyclosporin A (CSA) and tacrolimus (FK506) are efficacious in patients with steroid-refractory or steroid-dependent ulcerative colitis (UC). We retrospectively investigated patients with refractory UC treated with CNIs to elucidate the prognostic factors for a colectomy. Data from 59 patients (35 men and 24 women) were analyzed. CSA and FK506 were administered by intravenous infusion and peroral administration, respectively. The efficacy of the CNIs was assessed using Seo's complex integrated disease activity index. Categorical data analyses were also conducted. The results revealed that the response rates for CSA and FK506 were similar (CSA, 66.6%; FK506, 63.6%). However, oral FK506 had a slower onset of action than intravenous CSA. The risk factors for CNI non-responsiveness were: i) more than 10,000 mg of prednisolone used prior to CNI treatment; and ii) positivity for cytomegalovirus antigenemia (C7-HRP). The factors affecting the rate of colectomy were: i) CNI non-responsiveness; ii) more than 10,000 mg of prednisolone used prior to the initiation of CNI treatment; and iii) positivity for C7-HRP. The addition of azathioprine (AZA) following CNI treatment significantly reduced the incidence of colectomy. Our results revealed the prognostic factors affecting the efficacy of CNI therapy and the need for colectomy in patients with refractory UC. Importantly, some of these factors may be obtained prior to or shortly following the start of CNI treatment. Furthermore, AZA is an important agent for averting colectomy once a patient responds to CNIs.

Entities:  

Year:  2012        PMID: 23060930      PMCID: PMC3460266          DOI: 10.3892/etm.2012.545

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  24 in total

1.  Prediction of short-term outcome for patients with active ulcerative colitis.

Authors:  N Oshitani; T Matsumoto; Y Jinno; Y Sawa; J Hara; S Nakamura; T Arakawa; A Kitano; T Kuroki
Journal:  Dig Dis Sci       Date:  2000-05       Impact factor: 3.199

2.  Severe ulcerative colitis: prospective study of parameters determining outcome.

Authors:  Sanjay Kumar; Uday C Ghoshal; Rakesh Aggarwal; Vivek A Saraswat; Gourdas Choudhuri
Journal:  J Gastroenterol Hepatol       Date:  2004-11       Impact factor: 4.029

3.  Response of refractory colitis to intravenous or oral tacrolimus (FK506).

Authors:  Klaus Fellermann; Zita Tanko; Klaus R Herrlinger; Thomas Witthoeft; Nils Homann; Andreas Bruening; Diether Ludwig; Eduard F Stange
Journal:  Inflamm Bowel Dis       Date:  2002-09       Impact factor: 5.325

4.  Cytomegalovirus infection in patients with inflammatory bowel disease.

Authors:  R Vega; X Bertrán; M Menacho; E Domènech; V Moreno de Vega; M Hombrados; E Cabré; I Ojanguren; M A Gassull
Journal:  Am J Gastroenterol       Date:  1999-04       Impact factor: 10.864

5.  Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial.

Authors:  S Meyers; P K Lerer; E J Feuer; J W Johnson; H D Janowitz
Journal:  J Clin Gastroenterol       Date:  1987-02       Impact factor: 3.062

6.  Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis.

Authors:  M Cottone; G Pietrosi; G Martorana; A Casà; G Pecoraro; L Oliva; A Orlando; M Rosselli; A Rizzo; L Pagliaro
Journal:  Am J Gastroenterol       Date:  2001-03       Impact factor: 10.864

7.  Cytomegalovirus as an exacerbating factor in ulcerative colitis.

Authors:  E V Loftus; G L Alexander; H A Carpenter
Journal:  J Clin Gastroenterol       Date:  1994-12       Impact factor: 3.062

8.  Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies.

Authors:  Takuya Yoshino; Hiroshi Nakase; Satoru Ueno; Norimitsu Uza; Satoko Inoue; Sakae Mikami; Minoru Matsuura; Katsuyuki Ohmori; Takaki Sakurai; Satoshi Nagayama; Suguru Hasegawa; Yoshiharu Sakai; Tsutomu Chiba
Journal:  Inflamm Bowel Dis       Date:  2007-12       Impact factor: 5.325

9.  A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis.

Authors:  H Ogata; T Matsui; M Nakamura; M Iida; M Takazoe; Y Suzuki; T Hibi
Journal:  Gut       Date:  2006-02-16       Impact factor: 23.059

10.  Predictors and the rate of medical treatment failure in ulcerative colitis.

Authors:  B J Chakravarty
Journal:  Am J Gastroenterol       Date:  1993-06       Impact factor: 10.864

View more
  2 in total

1.  Cyclosporine Therapy as a Rescue Treatment in Steroid Refractory Acute Severe Ulcerative Colitis: A Real Life Data From a Tertiary Center.

Authors:  Sami Evirgen; Raim İliaz; Filiz Akyüz; Bilger Çavuş; Suut Göktürk; Aslı Örmeci; Özlem Mutluay Soyer; Bülent Baran; Binnur Pınarbaşı; Çetin Karaca; Kadir Demir; Fatih Beşışık; Sabahattin Kaymakoğlu
Journal:  Turk J Gastroenterol       Date:  2022-06       Impact factor: 1.555

2.  Prognostic factors affecting early colectomy in patients with moderate to severe ulcerative colitis treated with calcineurin inhibitors.

Authors:  Hiromitsu Ban; Shigeki Bamba; Atsushi Nishida; Osamu Inatomi; Makoto Shioya; Ken-Ichiro Takahashi; Hirotsugu Imaeda; Masaki Murata; Masaya Sasaki; Tomoyuki Tsujikawa; Akira Andoh
Journal:  Exp Ther Med       Date:  2016-05-16       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.